NY-CARESTREAM-HEALTH
20.2.2024 21:42:30 CET | Business Wire | Press release
Carestream Health will exhibit its expanding portfolio of innovative, industry-leading medical imaging solutions at the annual European Congress of Radiology (ECR) from 28th February to 3rd March in Vienna Building on its century-long foundation of imaging research science, the company will showcase its diagnostic imaging solutions that help improve clinical outcomes, enhance the imaging experience for users and patients, and strengthen the financial position of healthcare facilities.
“We understand that the radiology industry across the world is facing challenges such as a shortage of skilled staff and consequently radiologists are dealing with increased workload demands,” said Jane Moverley, International Sales Director, Digital Radiology. “This is why Carestream solutions add significant value to the imaging process. For example, our new DRX-LC Detector helps deliver high-quality, long-length imaging with a single exposure to deliver a more user-friendly workflow, optimize productivity, and ease the physical stress on radiographers. We are also showcasing our expanding line of X-ray solutions that deliver high-quality imaging to meet our customers’ needs at an affordable price.”
Solutions to Help Improve Clinical Outcomes
DRX-Compass X-ray System
- Exceptional image quality
- Scalable and upgradeable technology
- Available in floor-mount or OTC configuration
DRX-Revolution Mobile X-ray System
- Our original X-ray Room on Wheels offering provides superb image quality, maneuverability, and on-board storage.
- Robust functionality with Carestream’s most advanced image processing is available in a single platform.
- Low-profile design and flexibility mean you can easily capture images wherever you need them most.
Solutions to Enhance User and Patient Experience
DRX-LC Detector
- Captures long-length images with a single exposure
- Saves exam time and speeds up workflow
- Decreases retakes
- Allows a higher level of patient comfort
ImageView Software
- Provides high-image quality with AI and advanced image processing technology
- Delivers a quick and sleek operator experience via a single-screen workflow
- Allows users to track analytics on key parameters such as exposure rates and number of rejections
- Provides dose reporting
Solutions to Strengthen Financial Position
New DRX-Rise Mobile X-ray System
- Cutting-edge features in a fully-integrated, digital X-ray unit provide an affordable path to digital imaging.
- Efficiency-boosting features include two touchscreen displays, a state-of-the-art lithium battery, and in-bin detector charging.
- Bedside imaging minimizes disruption and helps deliver an improved patient experience.
DR Detectors
- These are the right detector for every facility, workflow, and budget.
- X-Factor capability lets you share detectors across your facility.
- Upgrade your existing film or CR systems to full wireless DR with a retrofit system and detector.
- Various cassette sizes let you choose the best fit.
Full Suite of Imaging Solutions on Display at ECR 2024
Carestream will also display additional imaging innovations at Expo X2-Booth 220 at ECR. These will include the DRX-Compass X-ray System, DRX-Rise Mobile X-ray System, and DRX-Revolution Mobile X-ray System, as well as our suite of DR Detectors.
Schedule an appointment to discuss Carestream’s latest innovations and other medical imaging solutions at ECR 2024.
About Carestream Health
Carestream is a worldwide provider of medical imaging systems; X-ray imaging systems for non-destructive testing; and precision contract coating services for a wide range of industrial, medical, electronic, and other applications—all backed by a global service and support network. For more information about the company’s broad portfolio of products, solutions, and services, please contact your Carestream representative, or call 1-888-777-2072, or visit www.carestream.com.
CARESTREAM is a trademark of Carestream Health.
“Rx only”
2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220770604/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press release
Inaugural event features leaders from Tata Consumer Products and Sun Pharma, highlighting India's growing role in global supply chain innovation Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 22:30:00 CET | Press release
European Commission approval based on data from Phase 3 STOP-HS1 and STOP-HS2, which showed that Povofortay® (povorcitinib) met the primary endpoint at Week 12 and delivered clinically meaningful, durable responses through Week 54 and was well tolerated 1,2 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on res
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press release
Bhatt to lead enterprise technology strategy, AI deployment, and cyber and information security in Executive Leadership Team role Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise work
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press release
Radiation-resilient Lattice Nexus FPGAs have operated as specified in TESAT optical communication terminals since 2025 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platf
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release
New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
